Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Rs. 40 cr buyback, 200% dividend announced
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Subscribe To Our Newsletter & Stay Updated
